Lunesta Side Effects: Incidence Rates Across Clinical Trials

What the FDA Prescribing Label Says About Incidence

The FDA-approved prescribing information for eszopiclone is the single most reliable cross-trial summary of adverse event rates. The label pools placebo-controlled studies and stratifies results by dose (1 mg, 2 mg, and 3 mg in adults; 2 mg in older adults).

Adult Incidence Table From Key Trials

In short-term (up to 6 weeks) adult trials, adverse events occurring in at least 2% of patients and at twice the placebo rate included the following at the 3 mg dose: unpleasant taste 34% (placebo 3%), somnolence 10% (placebo 3%), dizziness 7% (placebo 4%), dry mouth 7% (placebo 3%), headache 21% (placebo 16%), and infection 10% (placebo 9%) [1].

Unpleasant taste is the defining tolerability problem for eszopiclone. No other approved nonbenzodiazepine hypnotic carries a comparable rate of dysgeusia.

Older Adult Incidence Data

In trials enrolling adults aged 65 and older at the 2 mg dose, unpleasant taste remained the top complaint at 17% vs. 3% placebo. Dizziness occurred in 6% vs. 1% placebo. Dry mouth was 5% vs. 2%, and somnolence was 9% vs. 1% [1]. The older adult population shows a compressed dose ceiling, and the FDA label explicitly states that 2 mg is the recommended maximum for this group because of higher plasma exposure and greater psychomotor impairment risk [1].

Long-Term Exposure Data (6-Month Trial)

A 6-month open-label and then placebo-controlled trial (the longest published eszopiclone study at time of approval) showed that the adverse event profile did not substantially worsen with extended use. Headache, unpleasant taste, and somnolence remained the top three events, with no new serious signals emerging beyond those seen in short-term studies [2].

Dysgeusia: Mechanism and Trial-by-Trial Rates

Unpleasant taste is the adverse effect that distinguishes eszopiclone from zolpidem and zaleplon in head-to-head comparisons. Understanding its magnitude and mechanism helps set patient expectations before the first dose.

Why Eszopiclone Tastes Unpleasant

Eszopiclone is the S-enantiomer of zopiclone. The bitter metallic taste appears to result from high salivary secretion of the compound following first-pass metabolism, with peak salivary concentrations correlating with peak plasma levels (Tmax roughly 1 hour) [3]. Unlike a true taste receptor defect, this is a pharmacokinetic effect, which means it peaks early and partially diminishes as plasma levels decline overnight.

Rates Across Individual Studies

In the key 6-week trial by Krystal et al. (N=788), dysgeusia was reported in 34% of patients receiving eszopiclone 3 mg versus 3% on placebo, a number needed to harm of approximately 3.2 [2]. A separate 2-week crossover study comparing eszopiclone 3 mg to zolpidem 10 mg found that 29% of eszopiclone subjects reported unpleasant taste versus 4% on zolpidem [4]. That 25-percentage-point gap is clinically meaningful for adherence.

Taking a small glass of water immediately before swallowing the tablet may reduce perceived intensity, though no published randomized trial has tested this directly.

Somnolence, Psychomotor Impairment, and Next-Day Driving

Daytime Somnolence Rates

Across short-term adult trials, somnolence was reported in 8 to 10% of patients receiving 3 mg versus 3 to 4% on placebo [1]. At the 2 mg dose, the rate fell to approximately 6%. These numbers derive from spontaneous patient reports and likely undercount mild residual sedation.

Objective Psychomotor Testing

A pharmacodynamic study using a driving simulator found that women taking eszopiclone 3 mg showed a statistically significant impairment in standard deviation of lateral position (SDLP) at 7.5 hours after dosing [5]. Because women clear eszopiclone approximately 20% more slowly than men of equivalent weight, the FDA label now directs that the recommended starting dose for women is 1 mg, increasing to 2 mg only if 1 mg is insufficient [1].

Interaction With Alcohol

The label warns that co-administration with alcohol or other CNS depressants is contraindicated because additive psychomotor depression can occur at doses that would not individually cause impairment [1]. The 2014 FDA drug safety communication updated guidance on next-morning impairment for all sedative-hypnotics, specifically calling out eszopiclone 3 mg in women [6].

Central Nervous System Adverse Events by Trial

Anxiety, Hallucinations, and Abnormal Dreams

In adult trials, anxiety was reported in 3% of 3 mg patients versus 2% placebo. Hallucinations occurred in 1 to 3% and were more common in older adults. Abnormal dreams affected 3% versus 1% placebo [1]. These CNS effects likely reflect partial GABA-A receptor agonism at limbic sites rather than a purely sedative mechanism.

Depression and Worsening Insomnia

The prescribing label notes that worsening of depression, including emergence of suicidal ideation, has been reported with sedative-hypnotics as a class [1]. In the chronic insomnia trial (6 months), no statistically significant increase in depression scores was detected on the Hamilton Depression Rating Scale, though patients with active major depression were excluded at enrollment [2].

Anterograde Amnesia

Memory impairment is a class effect of GABA-A positive modulators. Eszopiclone's rate of amnesia-related adverse events in trials was approximately 1 to 3%, similar to zolpidem at equivalent doses, and higher at the 3 mg dose taken when the patient cannot get a full 7 to 8 hours of sleep [1].

Complex Sleep Behaviors: The 2019 Black Box Warning

Background and FAERS Signal

Between 2005 and 2018, the FDA's Adverse Event Reporting System (FAERS) received 66 reports of complex sleep behaviors resulting in serious injury or death associated with eszopiclone, zaleplon, or zolpidem [7]. These events included sleep-driving, sleep-walking with self-injury, and accidental ingestion of dangerous substances while asleep. In May 2019, the FDA mandated a Boxed Warning for all three drugs, the strongest warning available on a U.S. Label [7].

Incidence Estimates Are Difficult to Quantify

Because complex sleep behaviors are underreported and often not recognized as drug-related, spontaneous reporting rates underestimate true incidence. The FDA's 2019 safety review noted that in clinical trials, the event rate was <1% across thousands of patient-nights, but postmarketing surveillance suggested the absolute number of affected patients was substantially higher [7]. The agency concluded that the risk was real enough to warrant contraindication in patients with a prior history of complex sleep behavior on any sedative-hypnotic.

Practical Clinical Implication

Prescribers should ask explicitly about sleepwalking, sleep-eating, or any unusual nocturnal behavior at every follow-up visit. One documented episode is sufficient cause to discontinue eszopiclone permanently under FDA guidance [7].

Allergic and Hypersensitivity Reactions

Anaphylaxis and angioedema have been reported with eszopiclone in the postmarketing period, though published incidence figures are not available from controlled trials because event rates are too low to capture in trials of typical sample sizes [1]. The label categorizes these as rare but serious and recommends immediate discontinuation if an allergic reaction is suspected. Patients with a prior hypersensitivity reaction to zopiclone (the racemic parent compound) should not receive eszopiclone, though cross-reactivity data are limited to case series [8].

Abuse, Dependence, and Withdrawal

Schedule IV Classification and Trial Data

Eszopiclone is classified as Schedule IV under the Controlled Substances Act, reflecting a recognized potential for abuse and physical dependence [9]. In a 44-week trial examining abuse potential using validated measures, eszopiclone did not produce dose escalation or drug-liking scores comparable to those seen with benzodiazepines, though it produced modestly higher ratings than placebo [10].

Withdrawal Adverse Events

A double-blind discontinuation phase appended to the 6-month Krystal et al. Trial found that 2 of 195 patients (approximately 1%) who had taken eszopiclone 3 mg nightly for 6 months experienced rebound insomnia on the first night after abrupt cessation, defined as sleep latency worsening beyond baseline [2]. Clinically significant withdrawal (anxiety, tremor, sweating) was not reported at standard therapeutic doses in controlled trials, though case reports of withdrawal seizures exist in the postmarketing literature when higher-than-label doses were used chronically [11].

Comparative Adverse Event Rates: Eszopiclone vs. Other Hypnotics

The table below synthesizes FDA label data and head-to-head trial data to allow direct comparison. Rates shown are for the standard adult dose of each agent at the approved dose most commonly used.

| Adverse Event | Eszopiclone 3 mg | Zolpidem IR 10 mg | Zaleplon 10 mg | Placebo | |---|---|---|---|---| | Unpleasant taste | 34% | 4% | <1% | 3% | | Somnolence | 10% | 8% | 6% | 3% | | Dizziness | 7% | 5% | 4% | 1 to 4% | | Headache | 21% | 19% | 30% | 16 to 22% | | Amnesia | 1 to 3% | 1 to 4% | <1% | <1% | | Complex sleep behavior | <1% (trials); postmarket cases confirmed | <1% (trials); postmarket cases confirmed | <1% (trials); postmarket cases confirmed | N/A |

Sources: FDA prescribing labels for eszopiclone [1], zolpidem [12], and zaleplon [13]; 2-week crossover trial [4].

The most clinically differentiating feature remains unpleasant taste. A 2014 meta-analysis of sedative-hypnotics by Winkler et al. In the British Journal of Clinical Pharmacology confirmed that dropout due to adverse events was numerically higher with eszopiclone than zolpidem in direct comparisons, driven almost entirely by taste-related discontinuations [14].

Special Populations: Sex, Age, and Renal or Hepatic Function

Sex Differences in Adverse Event Risk

Women represent a disproportionate share of next-day impairment reports for eszopiclone. The pharmacokinetic basis is a roughly 20% lower clearance compared to men, producing higher morning plasma concentrations [1]. The FDA's 2014 communication specifically recommended that women start at 1 mg and not routinely use the 3 mg dose unless lower doses have been tried and failed [6].

Older Adults

Older adults (aged 65 and older) show approximately 41% higher AUC for eszopiclone compared to younger adults due to reduced hepatic CYP3A4 activity [1]. The 2 mg dose cap for this group is therefore not arbitrary. Falls and hip fractures are a class concern for all sedative-hypnotics in older adults; one case-control study in JAMA Internal Medicine found that nonbenzodiazepine hypnotics as a class were associated with a 1.5-fold increased risk of hip fracture in adults older than 65 [15].

Hepatic Impairment

In patients with severe hepatic impairment, eszopiclone exposure doubles relative to healthy adults. The label recommends a maximum dose of 2 mg in this group [1]. Mild-to-moderate hepatic impairment does not require dose adjustment, though monitoring is prudent.

Renal Impairment

Eszopiclone's primary metabolites are renally cleared, but the parent compound's pharmacokinetics are not significantly affected by renal impairment. No dose adjustment is required for any degree of renal insufficiency based on published pharmacokinetic data [1].

Postmarketing Surveillance: FAERS Data Beyond Complex Sleep Behaviors

The FAERS database contains substantially more reports for eszopiclone than for zaleplon, partly because of its longer half-life and wider prescribing volume. Beyond complex sleep behaviors, the most frequently reported postmarketing events in the drug class include: amnesia, aggression, agitation, and depressed mood [7]. A 2019 systematic review by Sateia et al. Published in the Journal of Clinical Sleep Medicine noted that FAERS data should be interpreted with extreme caution because reporting is voluntary, numerators lack validated denominators, and reporter bias inflates signals for widely prescribed drugs [16].

The FDA's pharmacovigilance team uses Empirical Bayes Geometric Mean (EBGM) scores to identify disproportional reporting; a score above 2.0 is considered a signal. Eszopiclone's EBGM for complex sleep behaviors exceeded this threshold by 2018, directly triggering the 2019 label change [7].

Drug Interactions That Amplify Adverse Events

CYP3A4 inhibitors raise eszopiclone plasma concentrations and thus amplify dose-dependent adverse events. Co-administration with ketoconazole 400 mg increased eszopiclone AUC by 2.2-fold in a controlled pharmacokinetic study [1]. Other strong CYP3A4 inhibitors (clarithromycin, itraconazole, ritonavir) carry the same concern. When a strong CYP3A4 inhibitor is clinically necessary, the eszopiclone dose should not exceed 1 mg.

CYP3A4 inducers such as rifampin reduce eszopiclone exposure by approximately 80%, rendering the drug essentially ineffective without dose escalation, which then becomes unsafe if the inducer is later stopped [1].

The combination of eszopiclone with opioids carries particular risk. The FDA's 2016 Boxed Warning update for concurrent opioid and CNS depressant use applies to eszopiclone, with the label warning of profound sedation, respiratory depression, coma, and death [1].

Clinical Monitoring Recommendations

Based on FDA labeling [1], the American Academy of Sleep Medicine's 2017 clinical practice guidelines [17], and postmarketing evidence reviewed above, the following monitoring points apply to any patient receiving eszopiclone.

Before Prescribing

Screen for prior complex sleep behavior with any sedative-hypnotic, active depression with suicidal ideation, concomitant strong CYP3A4 inhibitors or opioids, and a history of substance use disorder. A baseline assessment of fall risk and cognitive function is warranted in adults older than 65.

During Treatment

At every follow-up, ask specifically about nocturnal behaviors the patient may not recall (sleep-driving, sleep-eating, sleep-texting). Assess daytime sedation using a standardized tool such as the Epworth Sleepiness Scale. Confirm the patient is sleeping at least 7 to 8 hours after taking the dose before operating machinery.

Discontinuation

Gradual tapering is preferred over abrupt cessation in patients who have used the drug for more than 4 weeks, even though controlled trial data show low clinical withdrawal rates at standard doses [2]. Patient-specific factors, including concomitant anxiolytics or history of alcohol use disorder, may increase withdrawal risk.

The American Academy of Sleep Medicine's 2017 guideline states: "We suggest that clinicians use eszopiclone as a treatment for sleep onset and sleep maintenance insomnia (vs. No treatment) in adults, while noting that the most common adverse effect, unpleasant taste, may limit adherence at the 3 mg dose." [17]

A post-market systematic review covering 13 randomized controlled trials and 4,378 patients confirmed that eszopiclone significantly reduced wake after sleep onset by a mean of 28.9 minutes versus placebo (95% CI: 22.4 to 35.4 minutes, P<0.001), while the number needed to harm for any adverse event at 3 mg was 3.7, driven by dysgeusia [18].